A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)Jennifer L. Crombie, Matthew S. Davids, Jon Arnason et al.|Blood|2024Cited by 6
212 | SAVE (SAFE ACCELERATED VENETOCLAX ESCALATION): RESULTS OF A PROSPECTIVE, PHASE Ib STUDY OF VENETOCLAX WITH AN ACCELERATED DOSE RAMP‐UP IN PATIENTS WITH CLLJennifer L. Crombie, Matthew S. Davids, Il Young Ahn et al.|Hematological Oncology|2025Cited by 0
Glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with high-tumor burden follicular lymphoma: First results of a multicenter phase II trialReid W. Merryman, Joshua Brody, Gottfried von Keudell et al.|Blood|2025Cited by 0
A phase 1/2 study of duvelisib plus venetoclax in patients with relapsed/refractory CLL/SLL or Richter transformationJennifer L. Crombie, Matthew S. Davids, Christine E. Ryan et al.|Blood Advances|2026Cited by 0
SAVE, Safe Accelerated Venetoclax Escalation: A phase Ib study of obinutuzumab plus venetoclax with daily ramp-up in CLLJennifer L. Crombie, Matthew S. Davids, Inhye E. Ahn et al.|Blood Advances|2026Cited by 0